OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes Research and Clinical Practice (2017) Vol. 127, pp. 224-237
Closed Access | Times Cited: 18
André Scheen
Diabetes Research and Clinical Practice (2017) Vol. 127, pp. 224-237
Closed Access | Times Cited: 18
Showing 18 citing articles:
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis
Raffaele Marfella, Celestino Sardu, Maria Luisa Balestrieri, et al.
Diabetology & Metabolic Syndrome (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 85
Raffaele Marfella, Celestino Sardu, Maria Luisa Balestrieri, et al.
Diabetology & Metabolic Syndrome (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 85
Glucagon‐like peptide‐1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR α pathway
Lujin Wu, Ke Wang, Wei Wang, et al.
Aging Cell (2018) Vol. 17, Iss. 4
Open Access | Times Cited: 79
Lujin Wu, Ke Wang, Wei Wang, et al.
Aging Cell (2018) Vol. 17, Iss. 4
Open Access | Times Cited: 79
Non‐ST‐elevation myocardial infarction outcomes in patients with type 2 diabetes with non‐obstructive coronary artery stenosis: Effects of incretin treatment
Raffaele Marfella, Celestino Sardu, Paolo Calabró, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 3, pp. 723-729
Closed Access | Times Cited: 75
Raffaele Marfella, Celestino Sardu, Paolo Calabró, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 3, pp. 723-729
Closed Access | Times Cited: 75
Glucagon, from past to present: a century of intensive research and controversies
André Scheen, Pierre J. Lefèbvre
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 2, pp. 129-138
Closed Access | Times Cited: 30
André Scheen, Pierre J. Lefèbvre
The Lancet Diabetes & Endocrinology (2022) Vol. 11, Iss. 2, pp. 129-138
Closed Access | Times Cited: 30
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes Research and Clinical Practice (2018) Vol. 143, pp. 88-100
Closed Access | Times Cited: 55
André Scheen
Diabetes Research and Clinical Practice (2018) Vol. 143, pp. 88-100
Closed Access | Times Cited: 55
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 2, pp. 101325-101325
Closed Access | Times Cited: 27
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 2, pp. 101325-101325
Closed Access | Times Cited: 27
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Kenneth S. Hershon, Barbara R. Hirsch, Ola Odugbesan
Clinical Diabetes (2019) Vol. 37, Iss. 3, pp. 250-259
Open Access | Times Cited: 33
Kenneth S. Hershon, Barbara R. Hirsch, Ola Odugbesan
Clinical Diabetes (2019) Vol. 37, Iss. 3, pp. 250-259
Open Access | Times Cited: 33
The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
Yanzhen Ren, Yuzhang Chen, Wenbin Zheng, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Yanzhen Ren, Yuzhang Chen, Wenbin Zheng, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential
Michael Røder
Therapeutic Advances in Chronic Disease (2017) Vol. 9, Iss. 1, pp. 33-50
Open Access | Times Cited: 32
Michael Røder
Therapeutic Advances in Chronic Disease (2017) Vol. 9, Iss. 1, pp. 33-50
Open Access | Times Cited: 32
GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 3, pp. 193-196
Closed Access | Times Cited: 29
André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 3, pp. 193-196
Closed Access | Times Cited: 29
Pharmacological management of type 2 diabetes: what’s new in 2017?
André Scheen
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 12, pp. 1383-1394
Open Access | Times Cited: 22
André Scheen
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 12, pp. 1383-1394
Open Access | Times Cited: 22
Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 5, pp. 386-392
Closed Access | Times Cited: 18
André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 5, pp. 386-392
Closed Access | Times Cited: 18
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
Yi‐Hsuan Lin, Yu‐Yao Huang, Yi‐Ling Wu, et al.
Diabetology & Metabolic Syndrome (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Yi‐Hsuan Lin, Yu‐Yao Huang, Yi‐Ling Wu, et al.
Diabetology & Metabolic Syndrome (2018) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Metabolic syndrome in older women
Maria A. Shalina
Journal of obstetrics and women s diseases (2019) Vol. 68, Iss. 3, pp. 81-88
Open Access | Times Cited: 4
Maria A. Shalina
Journal of obstetrics and women s diseases (2019) Vol. 68, Iss. 3, pp. 81-88
Open Access | Times Cited: 4
Evaluation of Cardio-Metabolic Effects of Treatment with Incretin-Based Therapies in Patients with Type 2 Diabetes
Olga Montvida
(2018)
Open Access
Olga Montvida
(2018)
Open Access
Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ?
André Scheen
Médecine des Maladies Métaboliques (2022) Vol. 16, Iss. 4, pp. 336-342
Closed Access
André Scheen
Médecine des Maladies Métaboliques (2022) Vol. 16, Iss. 4, pp. 336-342
Closed Access
